Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 50 min ago
Peer-reviewedCC BYViruses

An Alternative Approach Against Resistent Infections: Long-Term Bacteriophage Therapy in Cystic Fibrosis.

  • Lia Nadareishvili1
  • Nata Nakaidze1
  • Mariam Dadiani1
  • Dea Nizharadze1
  • Elisabed Zaldastanishvili2
  • Nana Balarjishvili2
  • Lika Leshkasheli2
  • Mzia Kutateladze2
  1. 1Eliava Phage Therapy Center, 0160 Tbilisi, Georgia.
  2. 2George Eliava Institute of Bacteriophage, Microbiology and Virology, 0160 Tbilisi, Georgia.
Read full textPDFDOICite

Abstract

Cystic fibrosis (CF) is an autosomal recessive genetic disorder that disrupts ion transport across epithelial surfaces, impairing mucociliary clearance and predisposing patients to chronic, often refractory bacterial infections. At the Eliava Phage Therapy Center (EPTC) in Tbilisi, Georgia, we utilize bacteriophage preparations to treat chronic pulmonary infections caused by various bacterial pathogens, including Staphylococcus aureus, Pseudomonas aeruginosa, Achromobacter xylosoxidans, and Burkholderia cepacia. This case report describes the successful treatment of a CF-related infection in a male patient with a ΔF508 mutation using Pyophage and Intestiphage preparations, as well as customized phages developed against specific P. aeruginosa isolates. The efficacy of phage therapy was assessed by evaluating clinical improvement, pulmonary function, inflammatory markers, and bacterial burden. We observed improvement across all assessed parameters, including a complete eradication of P. aeruginosa in sputum culture tests. This case highlights the potential of phage therapy as a primary antimicrobial approach for the long-term management of pulmonary infections in patients with CF.

Related

  1. Bacteriophage Therapy in Cystic Fibrosis: Emerging Strategies for Managing Chronic Pseudomonas aeruginosa Infections.
    Ayona Puthenpurayil, Lauren Gordon, Joanne L Fothergill
    Drug design, development and therapyPeer-reviewedCC BY-NCFull textEcologyEurope PMC
  2. Bacteriophage therapy against multidrug resistant bacterial infections demonstrates clinical advances and engineering innovations between 2020–2026
    Ahmed J. Alzahrani
    Frontiers in MicrobiologyPeer-reviewedCC BYFull text5 citedEcologyMicrobiologyOpenAlex
  3. Bacteriophage susceptibility varies within chronic Pseudomonas aeruginosa lung infections
    N. S. Houpt, J. Vanderwoude, S. P. Diggle +1
    bioRxivPreprintCC BY-NCFull textEvolutionary biologybioRxiv
  4. Antibacterial activity of a newly identified phage-derived endolysin and its parental bacteriophage against clinical uropathogenic Escherichia coli
    W. Wesolowski, S. Bloch, G. Czerwonka +12
    bioRxivPreprintCC BY-NCFull textMicrobiologybioRxiv
  5. Integrating bacterial and viral genomic information enhances and extends the machine learning predictions of bacteriophage activity against pathogenic Escherichia coli
    D. L. Gally, A. T. Brown, A. Chalka +4
    bioRxivPreprintCC BY-NC-NDFull textMicrobiologybioRxiv

Cite

BibTeXRIS
BibTeX
@article{nadareishvili2026alternative,
  title = {{An Alternative Approach Against Resistent Infections: Long-Term Bacteriophage Therapy in Cystic Fibrosis.}},
  author = {Lia Nadareishvili and Nata Nakaidze and Mariam Dadiani and Dea Nizharadze and Elisabed Zaldastanishvili and Nana Balarjishvili and Lika Leshkasheli and Mzia Kutateladze},
  journal = {Viruses},
  year = {2026},
  month = sep,
  doi = {10.3390/v18101050},
  url = {https://europepmc.org/article/MED/42943970},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - An Alternative Approach Against Resistent Infections: Long-Term Bacteriophage Therapy in Cystic Fibrosis.
AU  - Lia Nadareishvili
AU  - Nata Nakaidze
AU  - Mariam Dadiani
AU  - Dea Nizharadze
AU  - Elisabed Zaldastanishvili
AU  - Nana Balarjishvili
AU  - Lika Leshkasheli
AU  - Mzia Kutateladze
PY  - 2026
DA  - 2026/09/22
JO  - Viruses
DO  - 10.3390/v18101050
UR  - https://europepmc.org/article/MED/42943970
AB  - Cystic fibrosis (CF) is an autosomal recessive genetic disorder that disrupts ion transport across epithelial surfaces, impairing mucociliary clearance and predisposing patients to chronic, often refractory bacterial infections. At the Eliava Phage Therapy Center (EPTC) in Tbilisi, Georgia, we utilize bacteriophage preparations to treat chronic pulmonary infections caused by various bacterial pathogens, including Staphylococcus aureus, Pseudomonas aeruginosa, Achromobacter xylosoxidans, and Burkholderia cepacia. This case report describes the successful treatment of a CF-related infection in a male patient with a ΔF508 mutation using Pyophage and Intestiphage preparations, as well as customized phages developed against specific P. aeruginosa isolates. The efficacy of phage therapy was assessed by evaluating clinical improvement, pulmonary function, inflammatory markers, and bacterial burden. We observed improvement across all assessed parameters, including a complete eradication of P. aeruginosa in sputum culture tests. This case highlights the potential of phage therapy as a primary antimicrobial approach for the long-term management of pulmonary infections in patients with CF.
SN  - 1999-4915
ER  -